Barbie, David A.

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer

Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 67

Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses

Yang, S., Sheffer, M., Kaplan, I. E., Wang, Z., Tarannum, M., Dinh, K., Abdulhamid, Y., Bobilev, E., Shapiro, R., Porter, R., et al. (2025) · Nature Biotechnology

Bacterial Cancer TherapyImmunotherapy and Immune Responses

Cited by 66

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy

Liu, S., Marneth, A. E., Alexe, G., Walker, S. R., Gandler, H. I., Ye, D. Q., Labella, K., Mathur, R., Toniolo, P. A., Tillgren, M., et al. (2018) · Blood Advances

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 33

RASA1/NF1-Mutant Lung Cancer: Racing to the Clinic?

Kitajima, S., & Barbie, D. A. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 23

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer

Nardi, F., Perurena, N., Schade, A. E., Li, Z.-H., Ngo, K., Ivanova, E. V., Saldanha, A., Li, C., Gokhale, P. C., Hata, A. N., et al. (2023) · Journal of Clinical Investigation

Lung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

Cited by 21